JérémieNoel

Collaborateur

Paris + 33.1.56.59.38.94

Contact

Partager

Jérémie Noel intervient dans les domaines du private equity, des fusions-acquisitions et du droit boursier.

Il assiste régulièrement des cibles, telles qu'Ivalua, Kalray, Less, Lifen, MirSense et Shippeo, et des investisseurs, tels qu'Alven Capital Partners, Andera Partners, Elaia Partners, Hi Inov, Idinvest Partners et Wellington Partners, dans le cadre d'opérations de capital-risque.

Jérémie Noel conseille des entreprises à fort potentiel de croissance, cotées ou non, sur des questions de droit des sociétés et lors de négociations commerciales.

Parmi les transactions représentatives de son expérience figurent les augmentations de capital d'Ivalua, Lendix, Less, MirSense et TRiCares, l'acquisition d'Availpro par AccorHotels et l'introduction en bourse de Kalray.

Expérience

  • Amolyt Pharma enters into definitive agreement to be acquired by AstraZenecaJones Day is advising Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Elaia Partners and Illuminate Financial lead $4 million financing of Composable PromptsJones Day advised Elaia Partners and Illuminate Financial as lead investors in the $4 million seed financing of Composable Prompts to spearhead enterprise adoption of large language models, through advanced governance, fine-grained security, and virtualization.
  • Bene Bono raises €10 million in financing roundJones Day advised Bene Bono, a French company engaged in the business of consumer food delivery service with an anti-waste approach, in the €10 million financing round led by AXA Ventures Partners with participation of 2050 and historical investors Stride VC and Project A.
  • Collective receives investment from Blossom CapitalJones Day advised Collective.work, a French-based company engaged in the development of a software solution for freelancers, in connection with its €7 million round of financing led by Blossom Capital.
  • Lifen raises $58 million in Series C financing roundJones Day represented Lifen, a French-based company that develops and operates a global communication platform to facilitate collaboration among physicians, in connection with a $58 million Series C round of financing led by Creadev and Lauxera Capital Partners.
  • Swile raises $200 million in Series D financingJones Day advised Swile, a French-based tech company that offers digital solutions for employee rewards and benefits through a custom card and app, in connection with its $200 million Series D round of financing led by SoftBank, alongside existing investors Index Ventures, Eurazeo and Bpifrance Large Venture.
  • Amolyt Pharma raises $80 million in Series B financing roundJones Day advised Amolyt Pharma, a French based company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its $80 million Series B round of financing co-led by Sectoral Asset Management and Andera Partners.
  • Revaia leads €22 million Series A financing round of HubloJones Day represented Revaia as lead investor in connection with the €22 million Series A round of financing of Hublo, a French company engaged in the development and operation of services for the management of staff replacements and recruitments for health and medico-social institutions, with participation by Acton Capital.
  • Stride.VC participates as lead investor in €1.5 million financing round of Hors NormesJones Day represented Stride.VC LLP as lead investor in the seed round of financing of Taste It d/b/a Hors Normes, a consumer food delivery service which fights against the waste of fruits and vegetables directly from producers at a lower price.
  • Planity raises €30 million in Series B financing roundJones Day represented Planity, a French company specialized in the edition, design, and marketing of appointment making, payments, point of sales, product management, and customer tools dedicated to professionals in the beauty industry, in connection with its €30 million Series B financing round led by Gaia Capital Partners, alongside historical investors Crédit Mutuel Innovation, BPI Digital Venture, Alven, and Eiffel Investment Group.
  • Open CNP participates as co-investor in €16 million Series B financing round of YesWeHackJones Day represented Open CNP SAS as participating historical investor in the €16 million Series B round of financing of YesWeHack, a French-based company that develops a platform dedicated to connecting organizations with IT security needs and a community of competent people, led by la Banque des Territoires (Caisse des Dépôts et Consignations Group) and Eiffel Investment Group.
  • 2050.do, Bpifrance, and BNP Paribas participates in €5.5 million Series A financing round of Fleurs d'IciJones Day represented 2050.do, Bpifrance, and BNP Paribas, with Kalian Group also participating, in connection with the €5.5 million Series A financing round of Fleurs d'Ici, a French-based company engaged in the business of distributing and selling flowers based on a short and ethical circuit.
  • Quadrille Capital invests in La Belle Vie (DELEEV)Jones Day advised Quadrille Capital SAS as co-lead investor alongside Left Lane Capital in the €25 million round of financing of La Belle Vie (DELEEV), a French-based company specialized in the activity of on-line grocery stores.
  • 360Learning raises $200 million in financing roundJones Day advised 360Learning, a French-based company having developed a collaborative learning SaaS platform to help companies unlock learning based on collective expertise, in connection with its $200 million round of financing led by Sumeru, Silver Lake, and Softbank.
  • Elephant leads $40 million Series B financing round of DidomiJones Day represented Elephant as a lead investor with Breega in the $40 million Series B financing of Didomi, a Paris-based consent and preference management platform for collecting and leveraging user consents and preferences for businesses.
  • Yousign raises €30 million in Series A roundJones Day advised Yousign, a French-based trust service provider issuing electronic certificates and software publisher of an electronic signature application, in connection with its €30 million Series A round of financing led by Lead Edge Capital Management, LLC with existing investor eFounders also participating.
  • Matera raises $43 million in Series B financing roundJones Day represented Matera SAS in connection with its $43 million Series B round of financing led by Mubadala Capital to turn residential building management into SaaS.
  • Alkemics sells company to SalsifyJones Day advised Alkemics SAS and its shareholders in the sale of the company to Salsify, Inc., which empowers brands by providing tools to track and analyze inventories, presentation, and sales of goods on digital shelves.
  • Back Market raises $335 million in Series D roundJones Day advised Back Market, a French company specialized in the development and exploitation of an online marketplace dedicated to refurbished products, in connection with its $335 million Series D round of financing led by General Atlantic with the support of Generation Investment Management as well as existing investors.
  • Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A participate in €8.5 million investment in PeopleSpheresJones Day represented Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A. in connection with their participation in a €8.5 million investment in PeopleSpheres, a Paris, France-based developer of a SAAS solution for HR.
    •

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.